Placebo News and Research

RSS

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Fetal and neonatal therapy combination may lessen the aftereffects of congenital CMV infection

A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.

28 Jan 2021

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

Researchers have demonstrated that the prime or prime-boost vaccination of Moderna vaccine in hamsters induced robust neutralizing antibodies, ameliorated weight loss, and suppressed SARS-CoV-2 replication in the airways.

28 Jan 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

Medicinal cannabis improves outcomes in Parkinson's patients

With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson's disease (PD).

27 Jan 2021

Recombinant SARS-CoV-2 protein vaccine less immunogenic but more antigenic than expected

Now, a new preprint research paper posted to the medRxiv server presents preliminary results of a stabilized SARS-CoV-2 pre-fusion spike protein vaccine expressed in a baculovirus system (CoV2 preS dTM), with two different adjuvant formulations.

26 Jan 2021

First-of-its-kind cardiovascular drug gets FDA approval based on study from Canadian VIGOUR Centre

The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure.

25 Jan 2021

Researchers show how to estimate long-term efficacy of COVID-19 vaccines

Researchers at the University of North Carolina and the Fred Hutchinson Cancer Research Center in Washington have developed a way to evaluate vaccines' long-term efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

24 Jan 2021

New maintenance treatment for AML shows strong benefit for patients

Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites.

22 Jan 2021

Study shows antidepressant drugs are largely ineffective for back and osteoarthritis pain

Antidepressant drugs are largely ineffective for back and osteoarthritis pain, despite being widely used for these conditions, suggests a review of the evidence published by The BMJ today.

20 Jan 2021

Antidepressants are not effective for treating back pain, osteoarthritis, shows study

Antidepressants are commonly used worldwide to treat pain, however new research from the University of Sydney shows they offer little to no help for people suffering chronic back pain and osteoarthritis and may even cause harm.

20 Jan 2021

Novel non-steroid topical cream can safely and effectively treat plaque psoriasis

Psoriasis is a chronic inflammatory skin disease characterized by erythematous (red) patches and plaques.

19 Jan 2021

Early administration of ivermectin could help reduce viral transmission in COVID-19 patients

A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission.

19 Jan 2021

Personalized neuromodulation approach provides relief from severe depression symptoms

Targeted neuromodulation tailored to individual patients' distinctive symptoms is an increasingly common way of correcting misfiring brain circuits in people with epilepsy or Parkinson's disease.

18 Jan 2021

Analysis supports phase 3 trials of Johnson & Johnson's COVID-19 vaccine

Researchers in the Netherlands, the United States, and Belgium have presented early-stage clinical trial results demonstrating the safety and efficacy of Johnson & Johnson's vaccine candidate for coronavirus disease 2019 (COVID-19).

17 Jan 2021

Combination therapy reduces recovery time in COVID-19 patients, clinical trial finds

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

16 Jan 2021

New combination treatment may provide relief for patients with methamphetamine use disorder

A new treatment that combines two existing medications may provide long-sought relief for many battling debilitating methamphetamine use disorder, according to a study to be published tomorrow in The New England Journal of Medicine.

15 Jan 2021

Drug found to be safe and effective for treating patients with obesity and type 2 diabetes

A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.

13 Jan 2021